Sopharma AD-SofiaWAR:SPH -3.60%67 Net Current Asset Value is zł0.12 as of Mar. 2026, which is 100% below its 10-year median of 29.70. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.46 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 75 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 97.33% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Sopharma AD-Sofia's net current asset value per share for the quarter that ended in Mar. 2026 was zł0.12.
The historical rank and industry rank for Sopharma AD-Sofia's Net Current Asset Value or its related term are showing as below:
WAR:SPH'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 16.31 Med: 29.7 Max: 536
Current: 62.5
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sopharma AD-Sofia was 536.00. The lowest was 16.31. And the median was 29.70.
WAR:SPH's Price-to-Net-Current-Asset-Value is ranked worse than 97.33% of 75
companies
in the Medical Distribution industry
Industry Median: 3.15
vs WAR:SPH: 62.50
Sopharma AD-Sofia (WAR:SPH) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Sopharma AD-Sofia Net Current Asset Value Related Terms
Sopharma AD-Sofia Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: Net Current Asset Value Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Price-to-Net-Current-Asset-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of zł0.12 mean?
Sopharma AD-Sofia (WAR:SPH) has a Net Current Asset Value of zł0.12 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sopharma AD-Sofia and its competitors. This is 100% below median its historical median of 29.70. Over the past decade, Sopharma AD-Sofia's Net Current Asset Value has ranged from 16.31 to 536.00. According to the industry distribution chart, Sopharma AD-Sofia ranks #73 out of 75 companies in the Medical Distribution industry, placing it in the top 97.3%.
Is Sopharma AD-Sofia's Net Current Asset Value too high?
Sopharma AD-Sofia's current Net Current Asset Value of zł0.12 is 100% below median its 10-year median of 29.70. Over the past 10 years, this metric has ranged from a low of 16.31 to a high of 536.00. Based on the distribution chart, Sopharma AD-Sofia ranks #73 out of 75 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Net Current Asset Value compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #73 out of 75 companies for Net Current Asset Value. This places Sopharma AD-Sofia in the lower half of its industry. The industry median Net Current Asset Value is 3.15. Historically, Sopharma AD-Sofia's own Net Current Asset Value has ranged from 16.31 to 536.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Distribution company?
The median Net Current Asset Value among Medical Distribution companies is 3.15, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Net Current Asset Value is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Net Current Asset Value is zł0.12, which is 100% below median its own 10-year median of 29.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.46, compared to a current price of zł7.50 — trading 44.3% below its estimated fair value. The current Net Current Asset Value is zł0.12, which is 100% below median its 10-year median of 29.70. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Net Current Asset Value is zł0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.50 is trading 44.3% below its estimated GF Value™ of zł13.46.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Net Current Asset Value: zł0.12 (100% below median its 10-year median of 29.70)
GF Value™: zł13.46 vs. price of zł7.50 (44.3% below fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
